

MarÃ-a Reig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5129924/publications.pdf>

Version: 2024-02-01

124
papers

15,961
citations

61945

43
h-index

17580

121
g-index

139
all docs

139
docs citations

139
times ranked

14524
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatocellular carcinoma. <i>Lancet, The</i> , 2018, 391, 1301-1314.	6.3	3,878
2	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	1.8	1,495
3	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2016, 150, 835-853.	0.6	1,365
4	Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. <i>Seminars in Liver Disease</i> , 2010, 30, 061-074.	1.8	945
5	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016, 65, 719-726.	1.8	883
6	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , 2016, 64, 1090-1098.	1.8	567
7	Management of HCC. <i>Journal of Hepatology</i> , 2012, 56, S75-S87.	1.8	509
8	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , 2012, 56, 1330-1335.	1.8	436
9	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 616-623.	2.0	403
10	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis. <i>Hepatology</i> , 2015, 61, 526-536.	3.6	286
11	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , 2018, 19, 682-693.	5.1	285
12	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , 2010, 51, 2020-2029.	3.6	268
13	Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2009, 50, 791-798.	3.6	253
14	Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy. <i>Annual Review of Medicine</i> , 2010, 61, 317-328.	5.0	229
15	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419.	1.3	218
16	Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design. <i>Hepatology</i> , 2013, 58, 2023-2031.	3.6	217
17	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , 2014, 61, 318-324.	1.8	203
18	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165

#	ARTICLE	IF	CITATIONS
19	Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , 2012, 56, 1317-1323.	1.8	159
20	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 61, 1481-1487.	6.1	154
21	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012, 56, 103-108.	1.8	142
22	HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 128-139.	1.8	139
23	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	8.2	132
24	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609.	1.8	127
25	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , 2018, 68, 16-24.	3.4	124
26	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , 2015, 275, 698-707.	3.6	115
27	Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. <i>Seminars in Liver Disease</i> , 2014, 34, 444-455.	1.8	112
28	Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. <i>Hepatology</i> , 2011, 54, 2238-2244.	3.6	101
29	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 283-292.e10.	2.4	94
30	Î±-Fetoprotein for Hepatocellular Carcinoma Diagnosis: The Demise of a Brilliant Star. <i>Gastroenterology</i> , 2009, 137, 26-29.	0.6	89
31	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 327-327.	0.8	80
32	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , 2017, 37, 109-118.	1.8	73
33	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 597-602.	0.8	72
34	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
35	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	1.8	67
36	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 593-604.	6.1	62

#	ARTICLE	IF	CITATIONS
37	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
38	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	3.6	55
39	Should Patients With NAFLD/NASH Be Surveyed for HCC?. <i>Transplantation</i> , 2019, 103, 39-44.	0.5	52
40	New trials and results in systemic treatment of HCC. <i>Journal of Hepatology</i> , 2018, 69, 525-533.	1.8	49
41	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2cm. <i>Journal of Hepatology</i> , 2015, 62, 150-155.	1.8	46
42	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , 2019, 1, 17-29.	2.6	45
43	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 16701-16717.	0.8	44
44	Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). <i>Journal of Hepatology</i> , 2021, 74, 1225-1233.	1.8	42
45	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. <i>Hepatology</i> , 2022, 76, 139-154.	3.6	42
46	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 482-491.	1.9	40
47	The TGF- β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?. <i>Cancers</i> , 2021, 13, 3248.	1.7	37
48	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	2.6	36
49	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2014, 32, 554-563.	0.8	33
50	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , 2010, 42, S242-S248.	0.4	31
51	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , 2017, 37, 136-139.	1.9	31
52	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4000-4000.	0.8	31
53	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 719-737.	1.0	29
54	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84.	4.2	29

#	ARTICLE	IF	CITATIONS
55	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	1.8	26
56	Performance of gadoteric acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , 2020, 30, 186-194.	2.3	25
57	Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 710-719.	0.2	25
58	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , 2009, 29, 148-158.	1.9	22
59	New Systemic Treatments in Advanced Hepatocellular Carcinoma. <i>Liver Transplantation</i> , 2019, 25, 311-322.	1.3	21
60	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 90.	1.7	21
61	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	1.2	20
62	Multidisciplinary Clinical Approach to Cancer Patients with Immune-Related Adverse Events Induced by Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 3446.	1.7	19
63	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	1.3	19
64	Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. <i>European Journal of Medical Genetics</i> , 2021, 64, 104313.	0.7	19
65	Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. <i>Estudio de 686 casos en 73 centros. Medicina Clínica</i> , 2017, 149, 61-71.	0.3	17
66	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , 2022, 76, 874-882.	1.8	17
67	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.1	16
68	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1923-1936.	0.9	15
69	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	1.9	15
70	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , 2020, 52, 1041-1046.	0.4	13
71	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , 2020, 12, 332.	1.7	13
72	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , 2021, 41, 598-607.	1.9	13

#	ARTICLE	IF	CITATIONS
73	Lenvatinib: can a non-inferiority trial change clinical practice?. <i>Lancet, The</i> , 2018, 391, 1123-1124.	6.3	12
74	Current pharmacological treatment of hepatocellular carcinoma. <i>Current Opinion in Pharmacology</i> , 2021, 60, 141-148.	1.7	12
75	Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents. <i>Viruses</i> , 2019, 11, 406.	1.5	11
76	Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. <i>Antioxidants</i> , 2021, 10, 1336.	2.2	11
77	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
78	Pattern of tumor progression in liver cancer: The missing partner in trial design. <i>Hepatology</i> , 2015, 62, 674-676.	3.6	10
79	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , 2021, 12, 555.	2.7	10
80	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2448.	1.4	10
81	Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria. <i>Hepatology</i> , 2022, 76, 1318-1328.	3.6	10
82	Systemic treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 921-935.	1.0	9
83	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , 2021, 75, 1154-1163.	1.8	9
84	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2015, 261, e105.	2.1	8
85	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , 2020, 30, 6694-6701.	2.3	8
86	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. <i>European Radiology</i> , 2021, 31, 4794-4803.	2.3	8
87	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). <i>Clinical practice guideline. Gastroenterology Y Hepatology (English Edition)</i> , 2018, 41, 328-349.	0.0	7
88	Riesgo de recurrencia del carcinoma hepatocelular en pacientes tratados con antivirales libres de interferón. <i>Gastroenterology Y Hepatology</i> , 2019, 42, 502-511.	0.2	7
89	Natural history and staging for hepatocellular carcinoma. <i>Clinical Liver Disease</i> , 2012, 1, 183-185.	1.0	6
90	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , 2016, 65, 864-865.	1.8	6

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , 2020, 40, 2476-2488.	1.9	6
92	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , 2022, 40, 428-428.	0.8	6
93	Sorafenib for Hepatocellular Carcinoma: Global Validation. <i>Gastroenterology</i> , 2009, 137, 1171-1173.	0.6	5
94	If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?. <i>Liver International</i> , 2013, 33, 1454-1456.	1.9	5
95	The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments. <i>Oncotarget</i> , 2017, 8, 106151-106152.	0.8	5
96	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 2048.	1.7	5
97	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , 2017, 149, 61-71.	0.1	4
98	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 426.	1.7	4
99	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: Could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , 2014, 61, 164-165.	1.8	3
100	Does ramucirumab deserve a second chance for liver cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 751-752.	5.1	3
101	Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals. <i>Gastroenterology Y Hepatología (English Edition)</i> , 2019, 42, 502-511.	0.0	3
102	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 263-270.	1.1	3
103	Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study. <i>Lancet Oncology</i> , The, 2022, 23, 4-6.	5.1	3
104	Treatment of Hepatocellular Carcinoma with Radioembolization: Gathering Assumptions for Trial Design. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1197-1199.	0.2	2
105	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.1	2
106	SAT-482-Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program. <i>Journal of Hepatology</i> , 2019, 70, e845.	1.8	2
107	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 655-661.	1.6	2
108	Reply to: Correspondence on the BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 1240-1241.	1.8	2

#	ARTICLE	IF	CITATIONS
109	POLYETHYLENE-GLYCOL DRUG-ELUTING EMBOLIC MICROSPHERES LOADED WITH DOXORUBICIN FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: FEASIBILITY, SAFETY AND PHARMACOKINETIC STUDY. Journal of Vascular and Interventional Radiology, 2022, , .	0.2	2
110	Medical treatments: in association or alone, their roles and their future perspectives. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 420-421.	1.4	1
111	The Search for an Effective Partner for Sorafenib: The Failure of Doxorubicin. Gastroenterology, 2011, 140, 1687-1688.	0.6	1
112	Systemic Treatment: Expecting Further Success. Digestive Diseases, 2015, 33, 590-597.	0.8	1
113	Reply to: "The reported "clear cut time association between interferon-free treatment and HCC" is anything but clear cut". Journal of Hepatology, 2020, 72, 1036-1037.	1.8	1
114	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. Oncotarget, 2021, 12, 440-449.	0.8	1
115	Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success. Oncotarget, 2018, 9, 33741-33742.	0.8	1
116	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. Gastroenterology Y Hepatología, 2022, , .	0.2	1
117	Evoluci3n natural y estratificaci3n del carcinoma hepatocelular. Clinical Liver Disease, 2013, 2, S333-S363.	1.0	0
118	Reply. Hepatology, 2015, 62, 978-979.	3.6	0
119	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules " A response". Journal of Hepatology, 2019, 71, 447-448.	1.8	0
120	Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 192-192.	1.9	0
121	Sorafenib and Clinical Patterns of Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 117-131.	0.1	0
122	THE COMPLEX MANAGEMENT OF HEPATOCELLULAR CARCINOMA: A MAJOR NEED OF EXPERTISE. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	0
123	Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoteric acid MR. Radiology and Oncology, 2022, 56, 292-302.	0.6	0
124	Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment. Gastrointestinal Disorders, 2022, 4, 141-152.	0.4	0